
|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
A Giant Stumbles
Author(s)Kevin Gopal
Basel, Switzerland—Roche, which recently slashed its work force by 3,000, maintains that it will remain independent even after the sale of 20 percent of the company to Novartis. Franz Humer, the troubled company’s chairman, says the founding family supports Roche’s strategy.
Advertisement
Articles in this issue
almost 25 years ago
Pharmacies: OTC Price Warsalmost 25 years ago
One Disease at a Timealmost 25 years ago
Overview of the Industry: A World of Opportunitiesalmost 25 years ago
The Power Shiftalmost 25 years ago
Overruled: No More Dual Pricingalmost 25 years ago
Submergedalmost 25 years ago
Generic ThreatNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement




